Issue 23, 2020
From the journal:

RSC Advances

Correction: Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy

Dongyang Tang,a   Xin Zhao,b   Tie Yangc  and  Cheng Wang*d  

* Corresponding authors

a Department of Experimental Center, Henan Institute of Science and Technology, Xinxiang, Henan 453003, P. R. China

b Department of Pharmacy, Xinxiang Central Hospital, Xinxiang, Henan 453000, P. R. China

c Nanjing Research Center, Jiangsu Chiatai Tianqing Pharmaceutical Co. Ltd, Nanjing, Jiangsu 210042, P. R. China

d College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China
E-mail: 11519016@zju.edu.cn

Abstract

Correction for ‘Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy’ by Dongyang Tang et al., RSC Adv., 2018, 8, 380–389.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D0RA90029J
Article type
Correction
Submitted
23 Mar 2020
Accepted
23 Mar 2020
First published
02 Apr 2020
This article is Open Access
Creative Commons BY license

RSC Adv., 2020,10, 13552-13552

Permissions

Request permissions

Correction: Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy

D. Tang, X. Zhao, T. Yang and C. Wang, RSC Adv., 2020, 10, 13552 DOI: 10.1039/D0RA90029J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements